WEC
IPXL

Winslow Evans & Crocker’s Impax Laboratories, Inc. IPXL Stock Holding History

Winslow Evans & Crocker’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-475
Closed -$12K – 1436
2013
Q4 		$12K Buy
+475
New +$10.6K ﹤0.01% 857

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Winslow Evans & Crocker's IPXL Position: Q1 2014 in Review

Winslow Evans & Crocker sold out of Impax Laboratories, Inc. (IPXL) in Q1 2014, closing a stake of 475 shares — an estimated $12K sold.

Winslow Evans & Crocker first reported a position in IPXL in Q4 2013 and held it in 1 quarter. The position peaked at $12K in Q4 2013. 181 funds tracked by Wall St. Rank hold IPXL as of Q1 2014.

  • Winslow Evans & Crocker reported no remaining Impax Laboratories, Inc. position as of Q1 2014 after selling out during the quarter.
  • Winslow Evans & Crocker sold 475 Impax Laboratories, Inc. shares in Q1 2014, an estimated $12K.
  • Winslow Evans & Crocker first reported a position in Impax Laboratories, Inc. in Q4 2013 and held it in 1 quarter.
  • Winslow Evans & Crocker's Impax Laboratories, Inc. position peaked at $12K in Q4 2013.
  • 181 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2014.

Based on Winslow Evans & Crocker's 13F filing for Q1 2014, filed 11 Apr 2014.